New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:14 EDTNE, ESV, DO, HK, INSM, AMGN, HIMX, ZGNX, DHI, TKMR, NNVC, PIKE, RIG, KORSOn The Fly: Pre-market Movers
HIGHER: Pike (PIKE), up 48% after signing a definitive merger agreement under which Court Square Capital Partners and the company's chairman and CEO will acquire the company in a transaction in which each of the company's shareholders will receive $12.00 per share cash... Amgen (AMGN), up 3.5% after the company reported its Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival... NanoViricides (NNVC), up 9% after starting anti-ebola virus drug development program. Tekmira (TKMR), which also has an anti-Ebola treatment under development, is up 8.8%... D.R. Horton (DHI), up 2% after Barron's says analyst see the stock reaching $31.00 per share in a year... Himax (HIMX), up 4% after upgraded at Lake Street. LOWER: Michael Kors (KORS), down 3.8% after Q2 guidance miss expectations, company says its sees FY15 gross margins to be down 50 bps... Zogenix (ZGNX), down 7% after resignation of Chief Commercial Officer Scott Shively... Transocean (RIG), down 2.3% after downgraded to Sell at Deutsche Bank. The firm also downgraded Diamond Offshore (DO) and Ensco (ESV) to Sell this morning and lowered its rating on Noble Corp. (NE) to Hold from Buy... Halcon Resources (HK), down 4.8% after downgraded at Morgan Stanley... Insmed (INSM), down 27% after announcing that, following discussions with European regulatory authorities, it intends to file by the end of 2014 a Marketing Authorization Application with the EMA for Arikayce.
News For KORS;RIG;PIKE;NNVC;TKMR;DHI;ZGNX;HIMX;AMGN;INSM;HK;DO;ESV;NE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
14:25 EDTAMGNAmgen urged by Third Point to split up
In its Q3 investor letter, Dan Loeb's Third Point said it is now one of Amgen's (AMGN) largest shareholders. Amgen's first steps to target its "inflated cost structure" should be applauded, but Third Point believes "much more can and should be done," the firm wrote. Immediate action Amgen can take to create shareholder value include focusing its R&D efforts, providing long-term margin guidance demonstrating a commitment to reducing costs and creating clarity on additional shareholder returns, Third Point also said. Additionally, Third Point said it believes that Amgen could benefit from a separation and should seriously consider breaking up into a "MatureCo" and a "GrowthCo." Shares of Amgen are up 4% to $143.12 in afternoon trading following the circulation of Third Point's Q3 investor letter.
14:09 EDTAMGNThird Point discloses new positions in eBay, Alibaba, exit from Sony
In its Q3 investor letter, Third Point says it established a "significant" position in eBay (EBAY). Dan Loeb's hedge fund also revealed it has established a significant direct investment in Alibaba (BABA) shares now that the company is public. Third Point also said it is now one of Amgen's (AMGN) largest shareholders. During the quarter, Third Point exited its position in Sony (SNE) and reduced or exited other positions, including AIG (AIG), Hertz (HTZ) and Softbank (SFTBF), the firm stated in its letter. PRICE ACTION: Following the disclosures in the Third Point letter, Amgen is up 4%, eBay is up 2.3% and Alibaba is up 3.8%, while Sony shares trading in New York are down nearly 1%.
13:56 EDTAMGNDan Loeb discloses position in Amgen at Robin Hood Conference, CNBC reports
Subscribe for More Information
10:57 EDTDODiamond Offshore volatility elevated into Q3 and volume outlook
Subscribe for More Information
09:48 EDTTKMRShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:21 EDTTKMRiBio valuation will be hard to maintain, TheStreet's Feuerstein says
iBio's current valuation will be hard to maintain "even under the best Ebola stockpiling scenario," TheStreet's Adam Feuerstein argues. He notes Ebola related stocks fell yesterday after the quarantines related to Thomas Duncan ended. Reference Link
07:15 EDTAMGNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
13:10 EDTKORSSteve Madden tumbles after providing preliminary Q3 results, FY14 outlook
Shares of shoe and accessory company Steve Madden (SHOO) are tumbling after the company announced preliminary third quarter results that were below analysts' consensus along with a reduction to its fiscal year 2014 outlook. WHAT'S NEW: Steve Madden announced that it is anticipating Q3 earnings per share to be approximately 61c-62c and net sales of $392M, below analysts' consensus estimates of 67c and $415.72M, respectively. The company noted that retail comparable store sales for the quarter are anticipated to be down 7.4%. Steve Madden also reduced its FY14 EPS outlook to $1.81-$1.86 from $2.00-$2.10, well below analysts' $2.02 consensus. The company lowered its net sales projection for the year, and now sees net sales up 1%-2% over fiscal year 2013 versus its previous net sales guidance for up 2%-4% over FY13. The new guidance factors in the recent acquisition of Dolce Vita and current expectations for remainder of the year. On August 14, Steve madden acquired Dolce Vita for $60.3M in cash and previously said the deal would be accretive to earnings in FY14 by 2c-3c and be "modestly accretive" in FY15. WHAT'S NOTABLE: Steve Madden's Chief Executive Officer Edward Rosenfeld said that the company's Q3 earnings were "disappointing" and were the result of weaker than expected retail segment performance. He believes that retail trends in the footwear space will continue to be difficult through the fourth quarter due to a lack of noteworthy fashion trends in the industry. The CEO said that the company's full-year guidance results from this pattern, along with a lowered reorder outlook in its wholesale segment. Rosenfeld is still confident, however, in the company's business model and believes that its acquisitions of Dolce Vita and its Mexican licensee will fuel the business forward over the long term. OTHERS TO WATCH: Competitors of Steve Madden include Michael Kors (KORS), Coach (COH), Kate Spade (KATE), and Vera Bradley. PRICE ACTION: During afternoon trading, shares of Steve Madden fell $2.62 or 8.2%, to $29.32. Over the last twelve months, the stock has fallen over 15%.
09:09 EDTTKMREMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:50 EDTDHID.R. Horton initiated with a Neutral at Buckingham
Target $23.
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
October 19, 2014
16:44 EDTTKMREbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
13:39 EDTTKMRCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTTKMRBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
10:00 EDTRIGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
08:06 EDTRIGTransocean downgraded to Market Perform from Outperform at Cowen
As previously reported Cowen downgraded Transocean to Market Perform from Outperform. The firm downgraded shares given the current market weakness, relatively older fleet and below average contracts for the next two years. Price target lowered to $30 from $39.
07:01 EDTRIGTransocean downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use